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This is the first report to describe a role for Lung Kruppel-like Factor
(LKLF or KLF2) in inflammatory airways diseases. In the present
study, we identify that LKLF is constitutively expressed in the small
airways of normal lungs; however, its expression disappears in
severe airway diseases, such as cystic fibrosis (CF) and chronic
obstructive pulmonary disease. LKLF from primary airway epithelial
cells inhibits NF-kB–driven transcription induced by Pseudomonas
aeruginosa 7-fold, but is down-regulated in the presence of TNF-a
and activated human neutrophils. As a constitutively expressed
protein, LKLF inhibits release of a key pro-inflammatory chemokine,
IL-8, from airway epithelia. Its expression by lung epithelial cells
is enhanced in the presence of TNF blockade. Thus, cytokine-
mediated inhibition of LKLF by neutrophils may contribute to
ongoing recruitment by promoting IL-8 release from airway epithe-
lia. We conclude that, in neutrophil-dominated airway environ-
ments, such as that seen in CF, reduced LKLF activity releases
a brake on pro-inflammatory cytokine production and thereby may
contribute to the persistent inflammatory responses seen in CF
airway disease.
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As the interface between the environment and the lung, airway
epithelia occupy a unique biological position. An appropriate
balance of host defense and tolerance is required such that
sustained epithelial activation does not occur. Inhaled patho-
gens and inflammatory stimuli are managed via the constitutive
and inducible responses of innate immunity. The inducible
response includes synthesis and secretion of chemokines and
cytokines into the submucosa, driving recruitment of phago-
cytes to eliminate invaders (1). Dysregulation of this process
may contribute to the pathological airway injury seen in diseases
such as cystic fibrosis (CF), diffuse panbronchiolitis, chronic
bronchitis, and asthma, due to persistent recruitment of in-
flammatory cells (2). Thus, understanding regulation of cellular
homeostasis in the airway is essential to approaching diseases
in which chronic immune activation leads to devastating con-
sequences.
In the CF airway, sustained activation of airway epithelium
contributes to the persistent recruitment of large quantities of
neutrophils to small and medium-sized airways, in response to
chronic Pseudomonas aeruginosa infection. Although contro-
versy exists over whether excessive inflammation may even
precede infection in early CF airways disease (4), there is no
question that decades of intense neutrophilic inflammation
contribute to airway damage and disease progression (3).
The Kruppel-like transcription factor family proteins play
ubiquitous roles in cellular functions of growth, differentiation
and apoptosis (5). Lung Kruppel-like Factor (LKLF or KLF2) is
widely known for its critical role in blood vessel development
during embryogenesis (6). In vascular endothelium, expression
of LKLF programs an atheroprotective phenotype, as an in-
hibitor of endothelial cell adhesive and thrombotic proteins,
vascular cell adhesion molecule (VCAM-1) and tissue factor, as
well as of pro-inflammatory transcription factor, NF-kB (7).
SenBanerjee and coworkers recently made an important obser-
vation regarding the expression of LKLF in the presence of
inflammatory cytokines. Although cytokines, in particular TNF-a
and IL-1, usually induce hundreds of genes, they potently inhibit
LKLF in endothelial cells (7, 8). As an activated endothelium sets
the stage for vascular disease, down-regulation of LKLF may
serve as one mechanism by which cytokines can maintain a pro-
inflammatory endovascular environment, so that pro-adhesive
and pro-thrombotic processes may occur (7, 8). LKLF plays
a pivotal role in maintenance of T lymphocyte quiescence (9). It
has been implicated in naive T cell survival, and its expression is
rapidly down-regulated upon T cell stimulation. Its role signifies
an active process by which T cells remain quiescent, avoiding
inappropriate immune activation, unless the appropriate inflam-
matory signals appear (9).
The present studies suggest a parallel role for LKLF in
airway epithelium. We show here that LKLF suppresses P.
aeruginosa–induced activation of NF-kB and subsequent IL-8
release from airway cells, but, in turn, its expression is inhibited
by pro-inflammatory cytokine TNF-a. Furthermore, we provide
evidence that LKLF is abundantly present in normal small
airway human tissue sections, but loses airway signal as in-
flammation worsens, and that the presence of activated human
neutrophils ‘‘switches off’’ LKLF in airway epithelial cells. Our
data establishes a counter-inflammatory role for LKLF in
airway epithelium, and provides evidence for cytokine regula-
tion of LKLF in a TNF-a–dependent fashion, suggesting that
LKLF down-regulation may be a mechanism by which the
presence of neutrophil secreted cytokines in the airway lumen
contribute to continuous activation of airway epithelium in CF
lung disease.
CLINICAL RELEVANCE
This is the first report describing the absence of anti-
inflammatory transcription factor Lung Kruppel-like Fac-
tor from the lungs of patients suffering from cystic fibrosis
(CF), contributing new data supporting the pathophysiol-
ogy of constitutive inflammation in CF lung disease.
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MATERIALS AND METHODS
Cell Culture and Reagents
Primary airway epithelial cells, derived from bronchial tissue from
normal lung donors, were grown on plastic with bronchial epithelial
growth media (10) to confluence. Tissues were obtained with consent
from patients using an Institutional Review Board–approved protocol
for harvest of lung tissue specimens at the time of lung transplant or
lung resection. The 2,122 non–small cell lung cancer cell line was
obtained from R. Winn (University of Colorado, Denver, CO). Human
TNF-a (R&D Systems, Minneapolis, MN) was added to epithelial
cultures at a concentration of 10 ng/ml. Antibodies for LKLF were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Plasmids
were generated or obtained from the following generous sources:
LKLF (Laurie Glimcher, Harvard University, Boston, MA), LKLF–
2-kb promoter–reporter construct (Jerry Lingrel, University of Cincin-
nati, Cincinnati, Ohio), Ad5CMV-EGFP and Ad5CMV-LKLF (gift of
Mukesh Jain, Harvard University, Boston, MA and generated at the
University of Iowa Viral Vector Core, Iowa City, IA), and full-length
iNOS promoter luciferase reporter construct (Ed Chan, National
Jewish Medical and Research Center, Denver, CO). A multiplicity of
infection of 10 plaque-forming units/cell was used to infect 98% of cells
growing on plastic in submerged culture. Recombinant human TNF-
binding protein (p55 soluble TNF receptor) was used at 10 mg/ml
(Amgen, Thousand Oaks, CA). The well-characterized P. aeruginosa
strain PAO1 was used, and LPS purified from both Pseudomonas and
Escherichia coli as previously described (11).
Western Blotting
A549 epithelial cells were exposed to TNF-a (10 ng/ml). After 4 hours
of exposure, control and TNF-treated cells were washed with cold PBS,
lysed in Radioimmunoprecipitation buffer (PBS, 1% Ipegal, 0.5%
sodium deoxycholate, 0.1% SDS, PMSF [10 mg/ml], aprotinin [30 ml/ml],
and sodium orthovanadate [1 mM]), pelleted at 14,000 rpm, and the
protein concentration of the lysate determined by Bradford assay.
Equal amounts of protein were separated by gel electrophoresis under
reducing conditions (1% b-mercaptoethanol) using 8 to 16% gels. The
proteins were then transferred to a PVDF membrane, and the mem-
brane was blocked in 1% nonfat milk and 0.1% Tween-20. Immuno-
detection was done with goat polyclonal anti-LKLF (Santa Cruz
Biotechnologies). Anti-goat secondary antibodies conjugated to horse-
radish peroxidase (HRP) at 1:10,000 dilution were used and detected
using ECL-plus (Amersham, Buckinghamshire, UK) (12). These experi-
ments were also performed with BEAS2B normal human bronchial
epithelial cell line (ATCC, Manassas, VA), with identical results.
Epithelial cells were infected with Ad5CMV-EGFP or Ad5CMV-LKLF
at a multiplicity of infection (MOI) of 10 and assessed for inducible nitric
oxide synthase (iNOS) protein expression at 24 hours in nuclear and
cytoplasmic fractions. Immunodetection was done with anti-iNOS
(Calbiochem, San Diego, CA) and ECL-plus as described above.
Nuclear and cytoplasmic fractionation was performed as per previously
published methods (13). Anti-phospho NF-kB p65 (ser 536) was
purchased from Cell Signaling (Danvers, MA).
Transient Transfection Assays
Primary human airway epithelial cells, passage 2, were grown in 6-well
plates to 80% confluence. In addition, the following cell lines were used
for this experiment: 16 HBE 14O- (from D. Gruenert, University of
Vermont, Burlington, VT), Nu-Li1 (from J. Zabner, University of Iowa,
Iowa City, IA) (14), and 2,122 and H157 non–small cell lung cancer cell
lines. Cells were transiently transfected with the following using Lip-
ofectamine and PLUS reagent (Life Technologies, Gaithersburg, MD):
1 mg LKLF or pCDNA empty vector control, 1 mg of pNF-kB luciferase
plasmid (Stratagene, La Jolla, CA), containing five NF-kB–binding sites
upstream of a luciferase reporter, and 1 mg of b-galactosidase to
normalize results for transfection efficiency. After 24 hours, cells were
exposed to Pseudomonas strain PAO1 at an MOI of 10:1 for 2 hours.
Each condition was done in triplicate. At the time of harvest, cells were
lysed with luciferase cell culture lysis reagent (Promega, Madison, WI).
Luciferase assays were performed using the Promega protocol for the
dual luciferase reporter assay system with a Monolight 2,010 lumin-
ometer (Analytical Luminescence Laboratory, San Diego, CA). All
results are expressed as luciferase units normalized to milliunits of b-
galactosidase, represent triplicate samples, and are representative of at
least three experiments. To evaluate the effect of TNF-a on NK-kB
reporter activity in the presence of LKLF, cells were transfected as
described above, then exposed 24 hours later to TNF-a (10 ng/ml) for 6
to 24 hours. For the LKLF reporter experiment, A549 cells were plated
1 day before transfection and transient transfection performed with
Lipofectamine and PLUS reagent according to manufacturer protocol.
One microgram of each plasmid was used for transfections and total
DNA kept constant. At 24 hours cells were exposed to TNF-a or
control carrier for 6 hours and then assayed for luciferase activity. For
the dose–response experiment, 2,122 epithelial cells were transiently
transfected with 1 mg pNF-kB luc, 1 mg b-galactosidase, and varying
amounts of LKLF vector, from 0 to 3 mg. Total amount of DNA was
kept constant. Luciferase assay was performed 24 hours after trans-
fection. All other constructs, including TRAF2, TRUSS, and IKKb,
were made in the Riches laboratory. In those transfections, the total
amount of DNA was kept constant, and lipofectamine transfection
performed as described above with pNF-kB luc and b-galactosidase for
transfection efficiency. For the iNOS reporter experiments, A549 cells
were plated and transfected as described above, using 1 mg iNOS luc,
1 mg b-galactosidase, and 1 mg of LKLF vector versus control vector.
Luciferase activity was measured at 24 hours and experiments done in
triplicate.
Electrophoretic Mobility Shift Assay
Nuclear extracts of 2,122 epithelial cells transduced with Ad5CMV-
LKLF or GFP control adenovirus were harvested 24 hours after
infection at an MOI of 10. Nuclear extracts were prepared by lysing
cell pellets with lysis buffer containing 10 mg/ml aprotonin, 10 mg/ml
leupeptin, and 1 mM PMSF, and nuclei extracted with buffer contain-
ing 20 mM Hepes, 10 mM NaCl, 1.5 mM MgCl2, 0.5 mM EDTA,
20% glycerol, and 0.5 mM DTT. Biotin end-labeled oligonucleotides
59-biotin-AGTTGAGGGGACTTTCCCAGGC-39 and 59-biotin-GCCT-
GGGAAAGTCCCCTCAACT-39 as well and nonlabeled oligonucle-
otide containing NF-kB consensus binding sequences were purchased
from Gene Link (Hawthorne, NY). The binding reactions contained
0.5 mg nuclear extract protein, buffer (10 mM Tris, pH 7.5 40 mM KCl,
5 mM MgCl2, l mM dithiothreitol, 0.05% Nonidet P-40, and 2.5%
glycerol), l mg/ml poly dI/dC, and 2 nM biotin-labeled DNA. The
reactions were incubated at room temperature for 20 minutes. Com-
petition reactions were performed by adding 200-fold excess of un-
labeled consensus oligonucleotide to the reaction mixture. The binding
reactions were electrophoresed on a 6% DNA denaturing gel, trans-
ferred to a nylon membrane and then treated with ultraviolet cross-
linking of DNA to the membrane. The biotin end-labeled NF-kB was
detected using streptavidin-HRP conjugate and LightShift Chemilumi-
nescent Substrate (Pierce, Rockford, IL) (15). The supershift analyses
were performed by incubating the DNA-binding reactions with anti–
NF-kBp65 (Santa Cruz Biotechnologies) for an additional 20 minutes
on ice before electrophoresis.
Enzyme-Linked Immunosorbent Assay for IL-8
IL-8 was measured by enzyme-linked immunosorbent assay (R&D
Systems) 24 hours after infection with adenoviruses: Ad5CMV-LKLF
and control adenovirus, Ad5CMV-EGFP.
Immunohistochemistry Analysis
Human lung histopathologic material from adults with CF (with
documented sweat chloride and genotyping) at the time of lung
transplant (n 5 3) was obtained. Control samples include specimens
from non-CF organ donors whose lungs were not used for transplant,
usually due to lack of match in area, age, or smoking history. Samples
included: control large airway (n 5 3); control distal lung (n 5 3); CF
large airway (n 5 3); CF distal lung (n 5 3); non-CF bronchiectasis
surgical wedge resections, infected with Mycobacterium avium intra-
cellulare (MAI) (n 5 3); and severe chronic obstructive pulmonary
disease (COPD) at the time of lung transplantation (n 5 3). Collection
of lung specimens at the time of transplant is approved by the
University of Colorado Combined Institutional Review Board (pro-
tocol 01–906). Using standard procedures, tissue specimens were
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incubated with LKLF primary antibody overnight or IgG staining
control at 48C using a 1:250 dilution in PBS/4% horse serum/0.1%
Triton-X100. Slides were rinsed and placed in Alexa-Fluor 594 (Mo-
lecular Probes) anti-goat secondary antibody at 1:1,000 dilution for 1
hour at room temperature. For confocal images, images were viewed
through the TRITC filter of an Olympus IX81 spinning disc confocal
microscope (Olympus, Center Valley, PA) and captured with a Hama-
matsu camera (Hamamatsu, Bridgewater, NJ), utilizing Intelligent
Imaging Slidebook v. 4.067 acquisition software (Intelligent Imaging
Innovations, Denver, CO). A standard S-curve was applied to all
darkfield images to set contrast, and a scale bar was placed digitally
(16). In addition, normal human primary epithelial cells, passage 2,
grown on slides, were fixed in formalin and then incubated with primary
antibody overnight or IgG control as described above. After 2 hours of
incubation with secondary antibody as above, slides were washed with
PBS and DAPI mounting media added, and images captured with
a Zeiss microscope with a scanning digital camera using the fluorescein
isothiocyanate filter and Axiovision software (Zeiss, Thornwood, NY).
Human Neutrophil Stimulation Experiments
Normal human neutrophils were isolated from healthy volunteers by the
plasma percoll method (Institutional Review Board Protocol -HS1285)
(17). Isolated neutrophils were left unstimulated or were stimulated with
P. aeruginosa–derived LPS (PA-LPS), 1,000 ng/ml, for 15 minutes at
room temperature. To analyze the effects of dead neutrophils on
epithelial cells, neutrophils were activated before cell lysis, as neutrophil
activation is required to achieve accumulation in the airway. After
stimulation, neutrophils were snap-frozen in liquid nitrogen for 18 hours.
Neutrophil death was defined by the loss of cell membrane integrity and
confirmed by trypan blue staining. Cellular contents of 106 neutrophils
were incubated with A549 cells, which were confluent on a 10-cm plate.
At specified time points, plates were washed three times with PBS and
epithelial cell lysates collected for Western blot. For studies using viable
neutrophils, A549 cells were exposed to LPS alone, unstimulated
neutrophils (106), or PA-LPS–stimulated human neutrophils (106) over
a time course. Plates were washed three times with PBS and neutrophils
counted in the washes to ensure against neutrophil protein contamina-
tion. For supernatant experiments, 106 neutrophils, which were either
unstimulated or stimulated with LPS, were added in RPMI to 10-cm
plates containing no epithelial cells for 4 hours. At 4 hours, media was
carefully removed and quickly spun at 14,000 rpm for 1 minute to pellet
neutrophils. This conditioned media was then added to confluent 10-cm
plates of A549 cells for 4 hours and epithelial cells lysates collected and
blotted for LKLF. All epithelial cell media was supplemented with
polymyxin B (10 mg/ml) on the date of the experiment, in order to
neutralize LPS, and neutralization of LPS was confirmed by Limulus
assay. The neutrophil/epithelial co-incubation experiments described
above were repeated, under conditions of TNF neutralization with
recombinant human TNF-binding protein (10 mg/ml). TNF neutraliza-
tion by TNFBP was confirmed by ECL assay as previously described (18).
TNF-binding protein was added both to human neutrophil media, as well
as to epithelial cells before co-incubation with human neutrophils.
Isolated neutrophils were left unstimulated or were stimulated with
LPS (100 ng/ml) for 15 minutes at room temperature. Neutrophils were
then coincubated with epithelial cells as described above, and epithelial
lysates collected at 24 hours for Western blot, after serial washes to clear
neutrophil presence. Each experiment was done a minimum of three
times.
Statistical Analysis
Results are represented as mean 6 SD. Quantitative differences
between control and test conditions were assessed statistically by
ANOVA, unpaired t tests, or correlation testing. P < 0.05 was con-
sidered statistically significant.
RESULTS
LKLF Is Absent in Diseases Characterized by Severe
Airway Inflammation
We analyzed lung tissue from normal donors to determine a site
for LKLF expression. In addition, we performed immunohisto-
chemistry for LKLF expression in multiple lung tissue speci-
mens representing three different diseases. The site of highest
expression in normal human lung, the small airways, demon-
strated punctate red signal (Figure 1A, top panel). In each of
three normal lung samples, a signal was present to the greatest
degree at the luminal aspect of bronchiolar cells. Comparisons
were made to lung tissues with varying degrees of airway
inflammation. In non-CF bronchiectasis, infected with non-
tuberculous mycobacteria, airway epithelia demonstrate trans-
location of LKLF from the apical cytoplasm to the nuclear
compartment. The area closer to normal lung (at the edges of
the surgical specimens) clearly demonstrates that LKLF has
translocated to epithelial nuclei. These peripheral areas of non-
CF bronchiectasis specimens demonstrate much stronger LKLF
signal than central areas, where active chromatin is less
condensed, and signal diminished adjacent to luminal cellular
debris. End-stage airway diseases were represented by sections
taken from patients with severe COPD and CF, at the time of
lung transplantation (n 5 3 each). Both COPD and CF tissue
sections were characterized by epithelial hyperplasia and
chronic inflammatory cell infiltration. Punctate red signal for
LKLF seen in normal and, to a lesser extent, in MAI lung, was
completely absent in all COPD and CF airway specimens
(Figure 1A, bottom two panels).
LKLF Localizes to the Cytoplasmic Compartment of Resting
Primary Airway Epithelial Cells
To characterize a site for LKLF expression in primary airway
epithelial cells from healthy human lungs, immunohistochemical
staining was performed on unstimulated primary airway cells,
passage 2, from healthy donors, demonstrating cytoplasmic
localization (Figure 1B). In addition, nuclear and cytoplasmic
fractions were isolated, and by Western blot, LKLF is primarily
present in cytoplasmic fractions in unstimulated airway cells
(Figure 1C). The faint signal present in nuclear fraction at
a slightly lower molecular weight may reflect processing which
occurs after transport to the nucleus.
LKLF Expression Inhibits NF-kB–Mediated Signaling in the
Presence of Pseudomonas
Given its role in regulating immune activation in T cells and in
endothelial cells, we hypothesized that LKLF may regulate
epithelial inflammatory cascades involved in the response to
pathogens. Primary airway cells were transfected with an NF-
kB–Luc reporter plasmid before exposure to Pseudomonas strain
PAO1. As shown in Figure 2A, the ability of Pseudomonas to
induce NF-kB luciferase activity was reduced 7-fold in LKLF
transfected airway cells. In primary airway cells, LKLF expres-
sion reduced NF-kB reporter activity to levels present in un-
infected airway cells (Figure 2A). NF-kB activity was inhibited by
LKLF in each cell type studied: 2-fold in 16 HBE 14O-, 4-fold in
Nu-Li1 cells, 3- to 6-fold in 2,122 and H157 lines, and finally 7-fold
in primary human airway cells (Figure 2A). LKLF reduction of
NF-kB reporter activity occurs in a dose-dependent manner
(Figure 2B).
We next used electrophoretic mobility shift assay (EMSA)
analysis to assess NF-kB nuclear binding in LKLF 1 airway cells.
Briefly, nuclear extracts were prepared from 2,122 cells trans-
duced with either control Ad5CMV-EGFP or Ad5CMV-LKLF
on three separate occasions. As shown in Figure 2C, binding of
biotinylated probes to nuclear NF-kB was significantly dimin-
ished in Ad5CMV-LKLF–infected cells. Supershift analysis of
NF-kB complexes performed with anti-p65 antibodies confirmed
the specificities of the binding complex. The reduction in p65
binding by EMSA appears to be secondary to sequestration of
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activated p65 (phosphorylated at serine 536) by LKLF in the
cytoplasm (Figure 2D). As shown in Figure 2E, downstream
effects of LKLF inhibition of NF-kB resulted in a reduction in
secreted neutrophil chemokine, IL-8. Measurement of IL-8 in cell
supernatants from GFP control versus Ad5CMV-LKLF–trans-
duced cells revealed reduced IL-8 release from LKLF 1 cells.
LKLF Expression Activates iNOS
LKLF overexpression in umbilical vein endothelial cells induces
endothelial nitric oxide synthase (eNOS) expression, an anti-
inflammatory regulator of vascular tone (7). In lung epithelia,
the mediator of nitric oxide (NO) release is iNOS. iNOS is
expressed constitutively by upper and lower airway epithelia,
induced in various airway inflammatory states, and dramatically
reduced in CF airways (19, 20). We evaluated LKLF effects on
iNOS expression. Ad5CMV-LKLF–transduced A549 cells up-
regulate iNOS in both nuclear and cytoplasmic compartments
compared with controls (Figure 3A). As shown in Figure 3B,
a 2.5-fold increase in iNOS promoter reporter activity was seen
in LKLF-transfected A549 cells compared with empty vector
transfected cells at 24 hours.
Figure 1. In vivo Lung
Kruppel-like Factor (LKLF)
expression in a spectrum
of airway diseases. (A)
Confocal images dem-
onstrate LKLF positivity
as red punctate staining
in the apical portions of
ciliated columnar epi-
thelial cells of normal
bronchiolar epithelium
in lung tissue sections
at 3630 magnification
using an Olympus IX81
spinning disk confocal
microscope. Bright cyto-
plasmic red signal is
most visible in normal
controls. In M. avium
intracellulare bronchiec-
tasis, LKLF has translo-
cated to the nucleus in
a region representing
the surgical margin
(n 5 3). In the center
of the non–cystic fibro-
sis (CF) bronchiectasis
tissue sections, in areas
of greater inflamma-
tion, chromatin has be-
come less condensed
and signal more faint.




disease and CF, at the
time of lung transplan-
tation, signal is com-
pletely absent (n 5 3
each). An IgG antibody
was used as a staining




cells grown in culture,
passage 2, versus IgG
antibody control (3400).
(C) LKLF localizes to cy-
toplasmic cell compart-
ments in passage 2
primary airway epithelial
cells blotted for LKLF.
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LKLF Expression by Airway Epithelial Cells Is Inhibited by
LPS-Stimulated Human Neutrophils
Neutrophil influx into CF airways is the pathological hallmark
of the severe persistent inflammation seen in CF lung disease.
We tested lung epithelial expression of LKLF in co-incubation
experiments, in the presence of stimulated and unstimulated
human neutrophils. A549 cells were treated with either: 1 3 106
unstimulated neutrophils or 1 3 106 neutrophils stimulated with
LPS. At 4 hours, stimulated neutrophils inhibited expression of
LKLF in A549 epithelial cells (Figure 4A). Epithelial cell
cytotoxicity was not observed with these quantities of neutro-
phils. A key question that arises is whether neutrophils must be
alive for this effect to occur. This distinction would imply
whether the effect is secondary to preformed elements or to
the neutrophil functional response. We subsequently exposed
A549 cells to dead human neutrophils, in quantities identical
to those used in the live human neutrophil experiments (Figure
4B). LKLF was expressed by epithelial cells co-incubated
with dead neutrophils. Its inhibition in epithelia requires co-
incubation with live stimulated human neutrophils, implying
that inhibition is a result of neutrophil functional activity. To
verify this hypothesis, we treated A549 cells with supernatants
of both unstimulated and LPS-stimulated neutrophils and con-
firmed that LPS-stimulated supernatant inhibits LKLF expres-
sion (Figure 4C).
TNF-a Inhibits LKLF Expression and Promoter Activity in
A549 Cells
While the list of neutrophil-secreted products is extensive, we
reasoned that LKLF, as a homeostatic protein expressed by
lung epithelia, may be regulated by local concentrations of
cytokines, indicating a possible mechanism by which neutro-
phils regulate LKLF expression. Others have reported that
TNF-a inhibits LKLF expression in endothelium (8). We sought
to establish whether this inhibition could be demonstrated in
lung epithelium. Human TNF-a was added to A549 epithelial
cultures for 6 hours. The effect of TNF-a upon LKLF reporter
activity, using a proximal 22 kb region of the LKLF promoter,
was assessed, and TNF-a diminished reporter activity by 50% at
this time point (Figure 5A). A549 cells were treated with TNF-a
Figure 2. Inhibition of
NF-kB activation by LKLF.
(A) Primary airway cells
were transiently trans-
fected with pNF-kB luc
and either control or
wild-type LKLF plasmid
for 24 hours, stimulated
with PAO1 at an MOI of






pNF-kB luc, and PAO1),
PA (includes pcDNA vec-
tor, pNF-kB luc, and
PAO1) *P , 0.001 ver-
sus 1PAO1 by unpaired




of LKLF vector ranging
between 0 and 3 mg
were used. Total amount
of DNA was kept con-
stant with control vec-
tor. Luciferase assay was
performed 24 hours af-
ter transfection. P 5
0.007 by correlation z
test (n 5 3). All luciferase
results shown as fold in-
crease in relative light
units and normalized for
transfection efficiency to
milliunits of b-galactosi-
dase. Data are means 6 SEM from three independent experiments. (C) Nuclear extracts were harvested from 2,122 epithelial cells express-
ing Ad5CMV-EGFP or Ad5CMV-LKLF. NF-kB band and supershift p65 band are shown. (D) A Western blot of cell fractions shows
predominance of activated p65 is sequestered in the cytoplasm of LKLF1 cells, while demonstrating total p65. (E) Supernatants of 2,122
cells overexpressing control Adv or Ad5CMV-LKLF were assayed for IL-8 by ELISA. *P 5 0.05 versus control via unpaired t test. Data expressed as
mean 6 SD.
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and expression of LKLF at 4 hours evaluated by Western blot.
As shown in Figure 5B, reduction of LKLF protein by TNF-a is
seen at 4 hours, which was seen at the identical time point in
Beas2B cells as well (data not shown). These data demonstrate
that TNF-a inhibits LKLF promoter activity, as well as protein
expression, in A549 and Beas2B epithelial cells.
LKLF Inhibition of NF-kB–Driven Transcription Is Regulated
by TNF Pathway Proteins
LKLF inhibits NF-kB in airway epithelial cells; however, this
effect is dependent upon activation of adaptor proteins of the
TNF receptor 1 (TNF-R1). Given its anti-inflammatory effects
in endothelium (7), we examined the effect of LKLF on NF-kB
activity in epithelial cell lines and primary airway cells. LKLF
markedly reduces NF-kB to one third of luciferase activity seen in
empty vector controls (Figure 6A). However, when co-transfected
with TNF signaling molecules TRAF2 and TRUSS, LKLF could
not reduce NF-kB reporter activity as effectively. We did not
observe direct binding between LKLF and TRAF2 by coimmu-
noprecipitation assay (data not shown). Within minutes of TNF-a
stimulation of TNF-R1, recruitment of effector molecules TRAF2,
TRUSS, and RIP (receptor-interacting protein), followed by
recruitment of IKKb to the TNF-R1 complex, occurs, leading to
downstream activation of NF-kB (21). Given its essential role in
TNF-induced NF-kB activation, we tested the effect of IKKb in
LKLF-mediated inhibition of NF-kB reporter activity. As shown
in Figure 6B, we found that LKLF once again inhibited NF-kB
reporter activity once IKKb was overexpressed in the presence of
LKLF.
Sustained Loss of LKLF Inhibition of NF-kB in the Presence
of TNF
Studies have demonstrated that in endothelial cells, inhibition
of LKLF by TNF-a is a sustained effect, lasting for up to 48
hours (8). To demonstrate that TNF-a inhibits LKLF’s func-
tional effects, in particular its ability to inhibit NF-kB in
epithelial cells, we transiently transfected wild-type LKLF
plasmid versus empty vector into A549 cells and subsequently
treated transfected cells with TNF-a for up to 24 hours. As
shown in Figure 7A, LKLF no longer inhibits NF-kB in the
presence of TNF-a at 24 hours. Using Western blot, we
demonstrate that A549 cells lose LKLF expression under
other pro-inflammatory conditions, specifically in the presence
of LPS-stimulated neutrophils at 24 hours. However, this loss
is TNF dependent, and expression is restored when TNF is
neutralized by p55 soluble TNF receptor (Figure 7B).
Figure 3. Induction of iNOS by
LKLF. (A) LKLF induces iNOS ex-
pression. A549 cells were in-
fected with control (GFPAdv) or
LKLFadenovirus (Ad5CMV-LKLF)
at an MOI of 10 for 24 hours and
Westernblotperformed for iNOS
expression. (B) LKLF induces
iNOS promoter activity. A549
cells were transiently co-trans-
fected with a full-length iNOS
promoter-luc plasmid and either
empty vector pcDNA3 or LKLF
wild-type plasmid and luciferase
activity measured at 24 hours.
*P 5 0.02 by unpaired t test. All
luciferase results are shown as
fold increase in relative light units
and normalized for transfection
efficiency. Data are means 6
SEM from three independent
experiments.
Figure 4. Inhibition of LKLF expression in epithelial cells by stimulated
neutrophils. (A) A549 cells were treated with either LPS, 106 unstimulated
neutrophils, or 106 LPS-stimulated neutrophils. Western blot for LKLF
expression at 1 hour up to 4 hours (n 5 3 for each experiment). (B) A549
cells incubated with dead neutrophils (stimulated with LPS before death)
for 4 hours, followed by Western blot for LKLF expression. (C) A549 cells
treated with four hour supernatants from LPS controls, unstimulated neu-
trophils, or LPS-stimulated neutrophils followed by Western blot for LKLF
expression. b-actin is shown as a loading control. PMN 5 neutrophil.
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DISCUSSION
A role for LKLF in maintaining airway homeostasis has not been
defined; however, its presence in uninfected airways free from
neutrophilic inflammation, down-regulation by TNF-a, and the
ability to reduce NF-kB reporter activity and increase iNOS each
suggest a function in the maintenance of lung epithelia.
Individual TNF scaffolding and adaptor proteins differ mark-
edly in their influence on the ability of LKLF to inhibit NF-kB
reporter activity. Previous investigations have explored TRAF2
regulation of LKLF expression. In TRAF2-null fibroblasts, ex-
pression of LKLF is absent, but is restored when TRAF2 is
reintroduced into the cells (22). As TRAF2 is a cytoplasmic
protein that does not shuttle to the nucleus and hence does not act
as a transcription factor, its regulation of LKLF in fibroblasts has
been described as indirect and p38 MAP kinase pathway de-
pendent (22). However, based on the results of immunohisto-
chemistry and cellular fractionation studies, LKLF appears to be
expressed in the cytoplasm of airway cells. Although we did not
detect a direct interaction by LKLF and TRAF2 or RIP by co-
immunoprecipitation (data not shown), luciferase cotransfec-
tions revealed that LKLF-mediated inhibition of NF-kB reporter
activity is regulated by TNF receptor scaffolding and adaptor
proteins, each critical for the crosslinking that leads to IKK
activation. TRUSS is a TNF-R1 scaffolding protein, which is
constitutively associated with unligated TNF-R1, as well as
directly interacting with TNF-R1 signaling proteins, TRADD
and TRAF2 (23). LKLF-mediated inhibition of NF-kB reporter
activity is diminished when TRAF2 and TRUSS are expressed
but unchanged in the presence of wild-type IKKb, whose activity
in the tripartite IKK complex is critical in the activation of the
classical NF-kB pathway (24). Although the mechanisms of
LKLF interaction with TNF receptor scaffolding proteins are
incompletely understood, the present data establish that, as
a transcription factor, LKLF is present in the cytoplasm, and that
its NF-kB inhibitory properties are dependent upon the proximal
TNF signaling proteins involved in TNF-R1 crosslinking up-
stream of IKK activation (23). Demonstrating this cytoplasmic
presence for LKLF supports its role as a protein which, though it
actively regulates inflammatory signaling from the nucleus (8), is
poised to be extinguished when appropriate extracellular in-
flammatory signals appear.
The present findings demonstrate that, similar to HUVECs,
epithelial cell LKLF is simultaneously inhibited by TNF-a and
able to inhibit NF-kB–driven signaling. This supports a role in
the maintenance of a resting epithelial cell phenotype, where a
tight rein on immune activation must exist, given the quantities
of aeroantigens and microorganisms present in the 10,000 liters
of air inhaled each day (1). Data from endothelial cell studies
demonstrate that LKLF expression is a means by which the
microvasculature regulates attachment and subsequent trans-
Figure 5. LKLF is inhibited by TNF-a. (A) Inhibition of LKLF promoter
by TNF-a. A549 cells were transiently transfected with a 2.0-kb LKLF
promoter and, after 24 hours of transfection, treated with TNF-a (10
ng/ml) for 6 hours. Luciferase assay was performed. *P , 0.001 by
unpaired t test. (B) Inhibition of LKLF expression in the presence of
TNF-a. Western blot of lysates from A549 cells treated with TNF-a for
4 hours. b-actin is shown as a loading control.
Figure 6. TRUSS and TRAF2, but not IKKb, reverse LKLF-mediated
inhibition of NF-kB. A549 cells were transiently transfected with pNF-
kB luciferase, as well as control vector or LKLF plasmid in the presence
or absence of TRAF2, TRUSS, or IKKb. Luciferase assay was performed
24 hours after transfection. (A) NF-kB activity is inhibited by trans-
fection with wild-type LKLF plasmid (*P , 0.001 versus empty vector);
this is rescued by cotransfection with either TRUSS or TRAF2 (P , 0.001
for difference from LKLF only by ANOVA). Co-transfection of TRUSS and
TRAF2 plasmids with wild-type LKLF significantly decrease NF-kB
activity from levels reached with TRUSS and TRAF2 plasmids alone
(****P 5 0.001 and *****P 5 0.0003, respectively, by ANOVA). Though
clearly reduced, NF-kB activity still remains significantly higher than
that seen with LKLF plasmid alone (**P 5 0.0015 for LKLF and TRUSS
versus LKLF alone, ***P 5 0.001 for LKLF and TRAF2 versus LKLF alone).
(B) NF-kB activity is again inhibited by transfection with wild-type LKLF
plasmid (*P , 0.001). A significant increase in NF-kB activity occurs
with IKKb (P , 0.0001). Cotransfection of wild-type IKKb plasmid with
wild-type LKLF reduces NF-kB activity to that seen with LKLF plasmid
alone (**P 5 ,0.001 for LKLF and IKKb versus IKKb alone, P 5 0.22 for
LKLF and IKKb versus LKLF alone, by ANOVA).
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migration of leukocytes into adjacent tissues, specifically by
inhibiting VCAM-1 and E-selectin (7). The present data suggest
a comparable role in lung epithelia, and particularly that anti–
NF-kB properties are significantly reduced when inflammatory
cytokines are present. Kumar and colleagues demonstrated
a nuclear mechanism for this reduction in HUVECs, where
p65 cooperates with histone deacetylase 4 to inhibit MEF2
induction of the LKLF promoter (8). In epithelial cells, LKLF
sequesters activated p65 in the cytoplasm, sharply reducing
nuclear binding as seen by EMSA, though direct interaction was
not demonstrated by co-immunoprecipitation.
A key neutrophil chemokine downstream of NF-kB activa-
tion is IL-8, and induction of LKLF leads to diminished IL-8
release into epithelial cell supernatants, indicating a role in the
regulation of neutrophil recruitment.
Furthermore, LKLF increases both expression and promoter
activity of iNOS, which is produced by neutrophils, macro-
phages, and epithelial cells in response to LPS and bacterial and
cytokine stimulation (25). Although CF airways are populated
with millions of bacteria, explanted CF bronchial epithelium
expresses less iNOS mRNA compared with non-CF bronchiec-
tasis tissue (26). Immunocytochemistry reveals little iNOS
expression in CF epithelia, stimulated or unstimulated, in the
presence or absence of neutrophils (27). Exhaled breath studies
of patients with CF show decreased NO concentrations com-
pared with nonsmoking control subjects (28). In animal studies,
inhaled NO reduces pulmonary sequestration of activated
neutrophils, and mice lacking iNOS have increased airway
neutrophil populations (29, 30). Thus, while the mechanism of
LKLF up-regulation of iNOS expression in epithelial cells is
unknown, the paucity of both in CF airways establishes multiple
levels upon which neutrophil recruitment to the airways may be
increased in their absence.
The present study establishes specific sites in the lung for
LKLF expression. In humans, LKLF is most highly expressed in
T lymphocytes, followed by heart, lung, and skeletal muscle
(31). LKLF has recently been shown to be a key transcriptional
regulator at yet another important interface, that between blood
and tissues. Its expression in endothelial cells is associated with
up-regulation of anti-inflammatory and anti-thrombotic eNOS
while inhibiting VCAM-1 and E-selectin adhesion molecules in
the presence of cytokines (7). SenBanerjee and coworkers
emphasize the association between LKLF function and its anat-
omical location. LKLF suppresses NF-kB–mediated VCAM-1
expression and its absence at branch points in the vascular tree,
where atherosclerosis is most likely to occur, posits a role in the
inflammatory processes of early atherosclerotic disease. The
immunohistochemistry images in this report establish anatomic
sites of LKLF activity in normal human lung tissue and its
waning expression as local inflammation intensifies. LKLF
appears to be most highly expressed in human small airways,
with less signal generated in alveolar tissue, and minimal ex-
pression seen in large airways. Since LKLF localizes to bron-
chioles, its expression in CF is of interest, as CF shares features
with another inflammatory airways disease, namely diffuse
panbronchiolitis. Both conditions manifest chronic airways bac-
terial colonization and marked neutrophilic infiltration ulti-
mately obliterating the small airways (32). The absence of
LKLF signal in CF small airways, along with its absence in
atherosclerotic disease sites, create a plausible role for this
protein in inflammatory diseases affecting two organs—the lung
and the vasculature. Given their marked presence in the CF
airway, we examined how neutrophils affect the induction of
LKLF in epithelial cells.
An unexpected finding of our study was that LPS-stimulated
neutrophils clearly inhibited LKLF release from epithelial cells.
Figure 7. Loss of LKLF mediated NF-kB inhibi-
tion in the presence of TNF-a. (A) Primary
airway cells were transiently transfected with
pNF-kB luc and either control or wild-type LKLF
plasmid for 24 hours, stimulated with TNF-a (10
ng/ml) for up to 24 hours and luciferase activity
measured. Ctrl (includes pcDNA vector and
pNF-kB luc), LKLF (includes LKLF vector and
pNF-kB luc) (P , 0.01 for LKLF versus control in
absence of TNF, P , 0.001 for LKLF in presence
versus absence of TNF). No statistical difference
between LKLF and pcDNA in presence of TNF,
by ANOVA (n 5 3). (B) A549 cells were co-
incubated with human neutrophils for 24 hours,
either in the presence or absence of TNF-bind-
ing protein. A Western blot depicts LKLF ex-
pression in the above conditions. Unstim PMN
indicates unstimulated neutrophils and stim
PMN indicates LPS-stimulated neutrophils.
TNFBP refers to TNF-binding protein (n 5 3).
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Since inhibition did not occur in the presence of dead LPS-
stimulated neutrophils, preformed neutrophil products are not
implicated. However, LKLF expression from A549 cells is
clearly inhibited in the presence of LPS-stimulated neutrophil
supernatants, and this suggests the involvement of a secreted
factor. Neutrophil functional responses are characterized by
release of superoxide anion, cytokines, and granule proteins.
Since TNF regulates LKLF expression, we reasoned that TNF-a,
coming from neutrophils, or from epithelial cells as a response
to neutrophil products, may be a mechanism by which neutro-
phils inhibit LKLF and can continuously activate the epithe-
lium. This inhibition implies that TNF-rich environments may
interfere with the ability of the epithelial cell to reestablish
homeostasis once an inflammatory response has occurred. The
concentration of neutrophils (106 per 5 million epithelial cells)
used in this analysis was based on bronchoalveolar lavage
sampling studies quantitating inflammatory cells before persis-
tent P. aeruginosa infection. In the absence of detectable
infection or endotoxin, bronchoalveolar lavage studies have
recovered neutrophils ranging from 104 to 106 per ml from the
airways of children, with an estimated recovery rate of approx-
imately 1 to 2% (4, 33, 34). An even broader range of quantity
of neutrophils has been isolated from children with CF during
early infection (33, 34).
The recruitment of neutrophils to small and medium-sized
airways in response to chronic P. aeruginosa infection is
emblematic of CF lung disease. By their teenage years, the
neutrophils in the lungs of patients with CF no longer eradicate
bacteria from their airways, but continue to accumulate. We
have identified LKLF as a transcription factor, present in
human bronchioles, that regulates NF-kB and IL-8 and in turn
is inhibited by neutrophils and TNF-a. Data from the present
study raise the possibility that, by inhibiting LKLF in airway
epithelial cells, neutrophils contribute to their own excessive
recruitment by promoting IL-8 release. Regulation of LKLF by
neutrophils provides a novel hypothesis as to how local CF
epithelial environments set the stage for an excessive and
prolonged primary inflammatory response. The current findings
suggest that LKLF may mark neutrophil airways activity and
their effects on epithelial anti-inflammatory responses, helping
to stratify patient populations in which anti-inflammatory
therapies may be more beneficial.
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